Here are the S-1 registration statements from Revium Recovery Inc (RVRC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow RVRC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVRC filings page.
Revium Rx filed Amendment No. 5 to its Form S-1 registration statement as an exhibits-only update. The company states that this amendment consists of the facing page, an explanatory note, the signature page, the exhibits index, and the filed exhibits, while the remainder of the registration statement is unchanged and therefore omitted. The filing also restates that the registrant may delay the registration statement’s effective date through further amendments and includes signatures from senior executives and directors, along with a power of attorney appointing an attorney-in-fact to sign future amendments.
Revium Rx is registering up to 1,562,500 units in a self-underwritten primary offering and up to 37,625,790 shares of common stock for resale by existing stockholders. Each unit is priced at $3.20 and includes two shares of common stock and one warrant exercisable at $2.40 for three years, creating up to 1,562,500 additional shares upon warrant exercise. The company expects about $4.4 million in net proceeds if all units are sold and plans to allocate roughly 70%–80% to developing its lipid-based drug candidates and clinical trials, and 20%–30% to exploring additional indications. Revium Rx had 60,729,100 shares outstanding before the offering. The resale shareholders may sell their 37,625,790 shares at $1.00 per share until an uplisting or national exchange listing, which the company warns could pressure its stock price and make the primary offering less attractive. As a preclinical biotech with a history of losses, the company highlights significant funding needs, extensive scientific, regulatory and IP risks, and additional geopolitical risks tied to its Israeli operations.
Revium Rx is registering up to 1,562,500 Units in a self-underwritten primary offering and up to 37,625,790 shares of common stock for resale by existing stockholders. Each Unit consists of two common shares and one warrant, offered at a fixed price of $3.20 per Unit, with expected net proceeds to the company of about $4.4 million if all Units are sold. Common shares outstanding would rise from 60,729,100 to 63,854,100, excluding shares issuable on new IPO warrants.
The company is a preclinical biotechnology business developing lipid-based drug delivery platforms for antimicrobial resistance, oncology and immunology, built around liposomal and nano-medicine technologies licensed from Hebrew University’s Yissum and acquired via its LipoVation transaction. Revium Rx has a history of losses, expects continued negative cash flow, and will need substantial additional funding beyond this offering.
Key risks include early-stage product candidates with no regulatory approvals, complex and uncertain clinical and regulatory paths, heavy reliance on licensed intellectual property, potential dilution from warrants and resales, penny-stock trading on the OTC market, and operational and geopolitical risks tied to significant R&D activities in Israel and multi-front regional conflict.